Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company received the Best IR Award, the Greatest IR Improvement Premium Companies, and the Best Continual IR Efforts Premium Companies at the 2023 IR Award hosted by the Japan Investor Relations Association (JIRA), the…
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today presented first-in-human data from a Phase 1 trial investigating AB-1002 (also known as NAN-101) for the treatment of patients with…
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test for Multiple Sclerosis (MS) received…
Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab demonstrated…
New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer’s Disease C2N Diagnostics, LLC (C2N), a leader in advanced brain health diagnostics, announced new findings that its blood biomarkers Aβ42/Aβ40 (amyloid-beta) and…
Marinus Pharmaceuticals inicia programa de acesso mundial para CV de suspensão oral do ZTALMY® (ganaxolona) –Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), uma empresa farmacêutica especializada no desenvolvimento de terapêuticas inovadoras para tratar distúrbios convulsivos, anunciou hoje o início do Marinus Access Program…
Gilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023 Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share 29 presentations, including 10 oral…
Biogen Appoints Monish Patolawala to its Board of Directors Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (“3M”), to the Company’s Board of Directors (the “Board”), effective January 1, 2024.…
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase III ALIGN study (NCT04573478) of…
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer GSK plc today announced positive headline results from a planned analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO…
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna’s mRNA platform to accelerate the development of vaccines against viral…
Boehringer Ingelheim’s SPEVIGO wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award Boehringer Ingelheim today announced that SPEVIGO® (spesolimab) has been recognized as Best Orphan/Rare Diseases Solution of 2023 by the Galien Foundation. The Prix Galien USA Award was…